CN1036341C - 咪唑衍生物的制备方法 - Google Patents
咪唑衍生物的制备方法 Download PDFInfo
- Publication number
- CN1036341C CN1036341C CN93102412A CN93102412A CN1036341C CN 1036341 C CN1036341 C CN 1036341C CN 93102412 A CN93102412 A CN 93102412A CN 93102412 A CN93102412 A CN 93102412A CN 1036341 C CN1036341 C CN 1036341C
- Authority
- CN
- China
- Prior art keywords
- compound
- general formula
- alkyl
- propyl
- sio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4207241 | 1992-03-07 | ||
| DEP4207241.7 | 1992-03-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1076192A CN1076192A (zh) | 1993-09-15 |
| CN1036341C true CN1036341C (zh) | 1997-11-05 |
Family
ID=6453463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93102412A Expired - Fee Related CN1036341C (zh) | 1992-03-07 | 1993-03-05 | 咪唑衍生物的制备方法 |
Country Status (25)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4010797A1 (de) * | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
| US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
| RU2109736C1 (ru) * | 1992-12-17 | 1998-04-27 | Санкио Компани Лимитед | Производные бифенила и способ их получения |
| FR2716883B1 (fr) * | 1994-03-04 | 1996-04-26 | Roussel Uclaf | Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant. |
| FR2716882B1 (fr) * | 1994-03-04 | 1996-04-05 | Roussel Uclaf | Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques. |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| US5856507A (en) * | 1997-01-21 | 1999-01-05 | Bristol-Myers Squibb Co. | Methods for the preparation of biphenyl isoxazole sulfonamides |
| CZ263098A3 (cs) | 1996-02-20 | 1999-05-12 | Bristol-Myers Squibb Company | Způsoby přípravy bifenylisoxazolsulfonamidů |
| US5939446A (en) * | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
| CA2274789A1 (en) * | 1996-12-13 | 1998-06-18 | Zymogenetics, Inc. | Compositions and methods for stimulating bone growth |
| EP0855392A3 (de) | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| AU6187898A (en) * | 1997-01-30 | 1998-08-25 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| AU748334B2 (en) | 1997-10-16 | 2002-05-30 | Board Of Regents, The University Of Texas System | Models and treatments for cardiac hypertrophy in relation with NF-AT3 function |
| DE19802969A1 (de) | 1998-01-27 | 1999-07-29 | Hoechst Marion Roussel De Gmbh | Verfahren zur Herstellung von S-Alkyl(Aryl)-substituierten Imidazol-Derivaten |
| DE19820064A1 (de) * | 1998-05-06 | 1999-11-11 | Hoechst Marion Roussel De Gmbh | Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| DE19832428A1 (de) * | 1998-07-18 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19832429A1 (de) * | 1998-07-18 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| JP2002540088A (ja) | 1999-03-19 | 2002-11-26 | ブリストル−マイヤーズ スクイブ カンパニー | ビフェニルイソキサゾール・スルホンアミド化合物の製造法 |
| US20040106647A1 (en) * | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
| US20040082613A1 (en) * | 2002-06-28 | 2004-04-29 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
| EP1631268A2 (en) * | 2003-05-21 | 2006-03-08 | Board Of Regents The University Of Texas System | Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure |
| WO2005003100A2 (en) | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| US8309562B2 (en) * | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| EP1685108B1 (en) * | 2003-11-03 | 2008-07-23 | Myogen, Inc. | 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease |
| CA2544763A1 (en) * | 2003-11-03 | 2005-05-12 | Myogen, Inc. | 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease |
| EP1699436A2 (en) * | 2003-12-12 | 2006-09-13 | Myogen, Inc. | Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
| US20060025463A1 (en) * | 2004-03-22 | 2006-02-02 | Michael Bristow | Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases |
| EP1737447A1 (en) * | 2004-03-22 | 2007-01-03 | Myogen, Inc. | (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases |
| CA2572179A1 (en) * | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| US8258145B2 (en) * | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| US20090220507A1 (en) * | 2005-07-22 | 2009-09-03 | Sucharov Carmen C | Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure |
| US20090306373A1 (en) * | 2005-12-20 | 2009-12-10 | Gamber Gabriel G | 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions |
| AU2007281261B2 (en) | 2006-08-01 | 2013-03-21 | Board Of Regents Of The University Of Texas System | Identification of a micro-RNA that activates expression of beta-myosin heavy chain |
| JP5587777B2 (ja) | 2007-07-31 | 2014-09-10 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 線維症をモジュレートするマイクロｒｎａファミリー及びその使用 |
| US8202848B2 (en) | 2008-03-17 | 2012-06-19 | Board Of Regents, The University Of Texas System | Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration |
| WO2012064743A2 (en) | 2010-11-08 | 2012-05-18 | The Johns Hopkins University | Methods for improving heart function |
| GB2605148A (en) * | 2021-03-23 | 2022-09-28 | Vicore Pharma Ab | New compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0324377A2 (en) * | 1988-01-07 | 1989-07-19 | E.I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids |
| EP0401030A2 (en) * | 1989-06-01 | 1990-12-05 | Merck & Co. Inc. | Angiotensin II antagonists |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
| US4355044A (en) * | 1980-12-19 | 1982-10-19 | Bernardo Heller | D-Phenylalanine treatment |
| CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
| US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
| DE4010797A1 (de) * | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
| US5135197A (en) * | 1990-08-30 | 1992-08-04 | Qualtec Data Products, Inc. | Equipment security method and apparatus |
| US5126342A (en) * | 1990-10-01 | 1992-06-30 | Merck & Co., Inc. | Imidazole angiotensin ii antagonists incorporating acidic functional groups |
| US5087634A (en) * | 1990-10-31 | 1992-02-11 | G. D. Searle & Co. | N-substituted imidazol-2-one compounds for treatment of circulatory disorders |
| CA2058198A1 (en) * | 1991-01-04 | 1992-07-05 | Adalbert Wagner | Azole derivatives, process for their preparation, and their use |
| US5236928A (en) * | 1991-03-19 | 1993-08-17 | Merck & Co., Inc. | Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists |
| EP0599999A1 (en) * | 1991-08-19 | 1994-06-08 | E.I. Du Pont De Nemours And Company | Angiotensin ii receptor blocking imidazolinone derivatives |
| DE4221009A1 (de) * | 1992-06-26 | 1994-01-05 | Bayer Ag | Imidazolyl-substituierte Cyclohexanderivate |
| RU2109736C1 (ru) * | 1992-12-17 | 1998-04-27 | Санкио Компани Лимитед | Производные бифенила и способ их получения |
-
1992
- 1992-08-21 TW TW081106607A patent/TW215434B/zh active
- 1992-12-21 CZ CS923811A patent/CZ281983B6/cs not_active IP Right Cessation
- 1992-12-21 SK SK3811-92A patent/SK279109B6/sk unknown
-
1993
- 1993-03-02 DE DE59310323T patent/DE59310323D1/de not_active Expired - Lifetime
- 1993-03-02 EP EP93103301A patent/EP0560177B1/de not_active Expired - Lifetime
- 1993-03-02 DK DK93103301T patent/DK0560177T3/da active
- 1993-03-02 ES ES93103301T patent/ES2187501T3/es not_active Expired - Lifetime
- 1993-03-02 AT AT93103301T patent/ATE230732T1/de active
- 1993-03-04 FI FI930970A patent/FI930970A/fi unknown
- 1993-03-04 NZ NZ247059A patent/NZ247059A/en unknown
- 1993-03-05 NO NO930817A patent/NO303632B1/no unknown
- 1993-03-05 CA CA002091135A patent/CA2091135A1/en not_active Abandoned
- 1993-03-05 RU RU93004577A patent/RU2116300C1/ru active
- 1993-03-05 ZA ZA931585A patent/ZA931585B/xx unknown
- 1993-03-05 CN CN93102412A patent/CN1036341C/zh not_active Expired - Fee Related
- 1993-03-05 PH PH45819A patent/PH31466A/en unknown
- 1993-03-05 JP JP04476993A patent/JP3542813B2/ja not_active Expired - Lifetime
- 1993-03-05 HU HU9300618A patent/HUT64041A/hu unknown
- 1993-03-05 KR KR1019930003270A patent/KR930019637A/ko not_active Application Discontinuation
- 1993-03-05 BR BR9300761A patent/BR9300761A/pt not_active Application Discontinuation
- 1993-03-05 PL PL93297955A patent/PL173023B1/pl unknown
- 1993-03-05 AU AU34011/93A patent/AU663565B2/en not_active Ceased
- 1993-03-05 MA MA23107A patent/MA22814A1/fr unknown
- 1993-03-07 IL IL104971A patent/IL104971A0/xx unknown
-
1995
- 1995-06-07 US US08/479,561 patent/US5604251A/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0324377A2 (en) * | 1988-01-07 | 1989-07-19 | E.I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids |
| EP0401030A2 (en) * | 1989-06-01 | 1990-12-05 | Merck & Co. Inc. | Angiotensin II antagonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1036341C (zh) | 咪唑衍生物的制备方法 | |
| CN1138546C (zh) | 用作细胞因子的某些1,4,5-三取代咪唑化合物 | |
| CN1038935C (zh) | 取代的联苯吡啶酮化合物及其盐的制备方法 | |
| CN1304390C (zh) | 新颖的γ—分泌酶抑制剂 | |
| CN1045769C (zh) | 新颖的咪唑亚硫衍生物的制备方法 | |
| CN1134420C (zh) | 新的取代咪唑化合物 | |
| CN1158279C (zh) | 作为血管紧张肽(1-7)受体兴奋剂的1-(p-噻吩基苄基)咪唑,其制备方法,其用途和含有它们的药物制剂 | |
| CN1078468A (zh) | 磺酰苄基取代的吡啶酮 | |
| CN1015054B (zh) | N-吲哚基乙基-磺酰胺类的制备方法 | |
| CN1832742A (zh) | 用于治疗心血管疾病的血管紧张素ii受体阻断剂氯沙坦、缬沙坦、坎地沙坦、替米沙坦、依普罗沙坦和奥美沙坦的硝基氧基衍生物 | |
| CN1377879A (zh) | 新的α－氨基酸磺酰基化合物、其制备方法和含有它们的药物组合物 | |
| CN1213307A (zh) | 新的取代的咪唑化合物 | |
| CN1214339A (zh) | 吡唑衍生物、其制备方法和在药物中的应用 | |
| CN1055361A (zh) | 取代吡咯，其制法，含该化合物制剂，及其应用 | |
| CN1560035A (zh) | 5－羟基吲哚－3－羧酸脂类衍生物 | |
| CN1113235A (zh) | 苯并咪唑、含这些化合物的药物组合物和其制备方法 | |
| CN1478081A (zh) | 取代的2-苯胺基苯并咪唑及其作为nhe抑制剂的用途 | |
| CN1071327C (zh) | 作为内皮素拮抗剂的苯并噻嗪二氧化物 | |
| CN1108257A (zh) | 杂环上取代的苯基-环己烷羧酸衍生物 | |
| CN1062289A (zh) | 治疗心、血管肥大及增生的方法 | |
| CN1080923A (zh) | 磺酰基苄基取代的苯并吡啶酮和吡啶并吡啶酮 | |
| CN1047084A (zh) | 具有酶抑制作用的二肽衍生物 | |
| CN1194978A (zh) | 苄氧基取代的稠合n杂环化合物,其制法及其作为缓激肽拮抗剂的用途 | |
| CN1167710C (zh) | 吡咯烷羰基氨基环状二硫化物 | |
| CN1119861A (zh) | 1-苯基-咪唑-2-酮联苯甲基化合物及其在治疗循环病症方面的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |